ӳ��ý

Publications

Author Correction: To boldly go where no microRNAs have gone before: spaceflight impact on risk for small-for-gestational-age infants.

Corti G, Kim J, Enguita FJ, et al. Author Correction: To boldly go where no microRNAs have gone before: spaceflight impact on risk for small-for-gestational-age infants. Communications biology. 2024;7(1):1339. doi:10.1038/s42003-024-07022-7

A latent Axin2/Scx progenitor pool is the central organizer of tendon healing.

Grinstein M, Tsai SL, Montoro D, et al. A latent Axin2/Scx progenitor pool is the central organizer of tendon healing. NPJ Regenerative medicine. 2024;9(1):30. doi:10.1038/s41536-024-00370-2

Alternate RNA decoding results in stable and abundant proteins in mammals.

Tsour S, Machne R, Leduc A, et al. Alternate RNA decoding results in stable and abundant proteins in mammals. bioRxiv : the preprint server for biology. 2024. doi:10.1101/2024.08.26.609665

Per- and poly-fluoroalkyl substances (PFAS) accelerate biological aging mediated by increased C-reactive protein.

Zhao Z, Zhou J, Shi A, et al. Per- and poly-fluoroalkyl substances (PFAS) accelerate biological aging mediated by increased C-reactive protein. Journal of hazardous materials. 2024;480:136090. doi:10.1016/j.jhazmat.2024.136090

Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.

Burr R, Leshchiner I, Costantino CL, et al. Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors. Nature cancer. 2024. doi:10.1038/s43018-024-00840-y

Per- and poly-fluoroalkyl substances (PFAS) accelerate biological aging mediated by increased C-reactive protein.

Zhao Z, Zhou J, Shi A, et al. Per- and poly-fluoroalkyl substances (PFAS) accelerate biological aging mediated by increased C-reactive protein. Journal of hazardous materials. 2024;480:136090. doi:10.1016/j.jhazmat.2024.136090

UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract.

Stritt K, Roth B, Masnada A, et al. UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract. Trials. 2024;25(1):682. doi:10.1186/s13063-024-08526-7

Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors.

Burr R, Leshchiner I, Costantino CL, et al. Developmental mosaicism underlying EGFR-mutant lung cancer presenting with multiple primary tumors. Nature cancer. 2024. doi:10.1038/s43018-024-00840-y

Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12.

Lewis TA, Ellermann M, Kopitz C, et al. Discovery of BAY 2666605, a Molecular Glue for PDE3A and SLFN12. ACS medicinal chemistry letters. 2024;15(10):1662-1667. doi:10.1021/acsmedchemlett.4c00336

UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract.

Stritt K, Roth B, Masnada A, et al. UROPOT: study protocol for a randomized, double-blind phase I/II trial for metabolism-based potentiation of antimicrobial prophylaxis in the urological tract. Trials. 2024;25(1):682. doi:10.1186/s13063-024-08526-7